Trials / Completed
CompletedNCT01072448
12-week Efficacy of Indacaterol
A 12-week Treatment, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Indacaterol in Patients With Chronic Obstructive Pulmonary Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 323 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Indacaterol 75 μg | Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. |
| DRUG | Placebo to indacaterol | Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2010-02-22
- Last updated
- 2011-08-19
- Results posted
- 2011-08-19
Locations
62 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01072448. Inclusion in this directory is not an endorsement.